| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Thrombin. Dermatan sulphate sodium selectively catalyzes the heparin cofactor II-mediated inactivation of thrombin and does not interact with antithrombin III. Thrombin is a serine protease that converts fibrinogen to fibrin, promoting blood coagulation. By accelerating thrombin inactivation, dermatan sulphate sodium exerts antithrombotic effects without affecting antithrombin III-mediated anticoagulation.
|
|---|---|
| ln Vitro |
Dermatan sulphate (10 μg/mL, 7 days) promotes neuronal differentiation and migration, but does not affect neurite outgrowth in human neural stem cells (hNSC). Dermatan sulphate (100 μg/mL, 12 days) promotes neuronal differentiation and enhances neurite outgrowth in mouse embryonic stem cells (mESCs). It significantly increased expression of neuronal markers (DCX, β-III-Tubulin) and significantly enhanced p-Erk1/2 expression.
|
| ln Vivo |
Dermatan sulphate sodium has antithrombotic activity in vivo. In a Bleomycin-induced pulmonary fibrosis model in C57 mice, Dermatan sulphate sodium (5.3 mg/kg, oral gavage, once daily for 28 days) significantly reduced lung index, alleviated pulmonary edema, inflammatory infiltration, alveolar damage and collagen deposition; reduced lung hydroxyproline and plasma fibrinogen levels; and increased plasma tPA levels.
|
| Enzyme Assay |
In vitro thrombin inhibition assays are performed using purified thrombin, heparin cofactor II, and chromogenic substrates (e.g., S-2238). Dermatan sulphate sodium is incubated with thrombin and heparin cofactor II, and the remaining thrombin activity is measured spectrophotometrically by monitoring substrate cleavage. IC50 values for thrombin inactivation are determined from dose-response curves.
|
| Cell Assay |
Human neural stem cells (hNSCs) and mouse embryonic stem cells (mESCs) are treated with Dermatan sulphate sodium at various concentrations (10-100 μg/mL) for 7-12 days. Neuronal differentiation is assessed by expression of neuronal markers (DCX, β-III-Tubulin) using qPCR or immunocytochemistry. p-Erk1/2 expression is measured by Western blotting.
|
| Animal Protocol |
Bleomycin-induced pulmonary fibrosis model in C57 mice: mice are administered Dermatan sulphate sodium (5.3 mg/kg, oral gavage, once daily for 28 days). Lung index, pulmonary edema, inflammatory infiltration, alveolar damage, and collagen deposition are assessed by histopathology. Hydroxyproline levels in lung tissue and plasma fibrinogen and tPA levels are measured.
|
| ADME/Pharmacokinetics |
Dermatan sulphate sodium exhibits high bioavailability after oral administration. It is absorbed from the gastrointestinal tract and distributed to various tissues. It is metabolized and excreted primarily in urine. Pharmacokinetic parameters (Cmax, Tmax, AUC, t1/2) have been evaluated in preclinical studies. It is typically stored at 4°C sealed, away from moisture and light.
|
| Toxicity/Toxicokinetics |
Dermatan sulphate sodium is generally well-tolerated with a favorable safety profile. As an antithrombotic agent, it may increase bleeding risk. In animal studies, it was tolerated at therapeutic doses. Standard toxicology studies are required for therapeutic development. As a research compound, detailed toxicology data are limited.
|
| References | |
| Additional Infomation |
Cholesteryl heptadecanoate is a cholesterol ester internal standard used for accurate determination of free cholesterol concentration in cells without hydrolyzing triglycerides. It can be used for quantitative determination of cholesterol esters by GC or LC mass spectrometry. CAS: 24365-37-5. Molecular formula: C44H78O2, molecular weight: 639.09. Synonyms: cholesteryl margarate, heptadecanoic acid cholesteryl ester, margaric acid cholesteryl ester. For research use only.
|
| Exact Mass |
477.078
|
|---|---|
| CAS # |
54328-33-5
|
| PubChem CID |
4368136
|
| Appearance |
White to off-white solid powder
|
| Index of Refraction |
-68 ° (C=1, H2O)
|
| LogP |
-4.9
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
31
|
| Complexity |
755
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(=O)(=O)([O-])O[C@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H]([C@@H]([C@H](C(=O)[O-])O1)O)O)O)NC(C)=O)O
|
| InChi Key |
AVJBPWGFOQAPRH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H23NO15S/c1-3(17)15-5-10(9(30-31(24,25)26)4(2-16)27-13(5)23)28-14-8(20)6(18)7(19)11(29-14)12(21)22/h4-11,13-14,16,18-20,23H,2H2,1H3,(H,15,17)(H,21,22)(H,24,25,26)
|
| Chemical Name |
6-[3-acetamido-2-hydroxy-6-(hydroxymethyl)-5-sulfooxyoxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~100 mg/mL (with sonication)
DMSO :~< 1 mg/mL (insoluble or slightly soluble) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
